How ATI works (biologically), page-31

I thought you'd made the wrong decision to sell out over $0.50, but you were correct and brave to do so with a view to buying back in - personally I have been invested in this stock to a degree since its 2014 IPO and daren't sell out now on the verge of the ATI announcement (but understand many are sceptical of OCC's ATI timeline) and what I thought was solid Insto's interest in that. Volumes are thin and as you say small cap health selling across the board (MSB was +5% early and -3% in the afternoon). I too am bullish long-term on health care, or more precisely bio-tech. I am on MSB and PAR too. OCC is by far my favourite of the three. I am utterly convinced of the efficacy of CelGro and ATI as is obvious from my posts. I don't get how Insto's started to pick up on the stock late 2019 and have abandoned since the CR. Being anchored to $0.50 perhaps a $0.48-52 range for a few weeks would not have surprised me, but $0.45...

Clearly the stock was pushed up too high on trial results and management spinning to Insto's in the latter half of 2019 - there were some heavy volumes going through Oct/Nov before the CR from 50's through low 60's. Those large buy volumes have all but disappeared and enough sellers eager to get out and not enough buyers to hold the pressure - where are those oversubscribed Insto's at $0.50? I don't blame present some holders selling out, its hard to hold your proverbials across a capital raising hangover, particularly if you bought in $0.60+.

Hopefully the CelGro TGA announcements will come soon and provide some buoyancy. I have written another mail to OCC management criticising the ATI delays - effectively daring them to delay again I am not privy to which surgeon is administering the ATI trial of course, but the recruitment has not been completed quickly enough by any measure - he/she needs to pull her finger out for the one or two allegedly outstanding patients. Its annoying, because I am utterly convinced from previous trials they will be good. It appears the market has overall gotten tired of the wait...